A Phase I/II Partially Randomized, Active-controlled Observer-blind, Dose-selection, Safety and Immunogenicity Study of GLB-COV2-043, an mRNA Vaccine Candidate Against SARS-CoV-2, Administered as a Single-vaccination Booster to Previously Vaccinated Adults is a PHASE1 clinical asset sponsored by GreenLight Biosciences, Inc. in COVID-19. SEO and diligence focus: GLB-COV2-043, BNT162b2/COMIRNATY®, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.